Improvement in the mobility of a patient with fibroblast growth factor 23-related hypophosphatemic osteomalacia and decompensated liver cirrhosis in response to burosumab: a case report-Reference-Cited by-同舟云学术

Improvement in the mobility of a patient with fibroblast growth factor 23-related hypophosphatemic osteomalacia and decompensated liver cirrhosis in response to burosumab: a case report

Published:2023 Issue:4 Volume:70 Page:419-426
ISSN:0918-8959
Container-title:Endocrine Journal
language:en
Short-container-title:Endocr J

Author:

Toi Norikazu¹,Imanishi Yasuo¹,Nagata Yuki²,Kurajoh Masafumi¹,Morioka Tomoaki¹,Shoji Tetsuo²,Shinto Yoshitaka³,Emoto Masanori¹

Affiliation:

1. Department of Metabolism, Endocrinology, and Molecular Medicine, Osaka Metropolitan University Graduate School of Medicine, Osaka 545-8585, Japan

2. Department of Vascular Medicine, Osaka Metropolitan University Graduate School of Medicine, Osaka 545-8585, Japan

3. Shinto Orthopedics and Rheumatology Clinic, Osaka 545-0052, Japan

Publisher

Japan Endocrine Society

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism

Link

https://www.jstage.jst.go.jp/article/endocrj/70/4/70_EJ22-0520/_pdf

Reference25 articles.

1. 1 Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, et al. (2004) FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 19: 429–435.

2. 2 Crotti C, Bartoli F, Coletto LA, Manara M, Marini E, et al. (2021) Tumor induced osteomalacia: a single center experience on 17 patients. Bone 152: 116077.

3. 3 Minisola S, Peacock M, Fukumoto S, Cipriani C, Pepe J, et al. (2017) Tumour-induced osteomalacia. Nat Rev Dis Primers 3: 17044.

4. 4 Chong WH, Molinolo AA, Chen CC, Collins MT (2011) Tumor-induced osteomalacia. Endocr Relat Cancer 18: R53–R77.

5. 5 Florenzano P, Gafni RI, Collins MT (2017) Tumor-induced osteomalacia. Bone Rep 7: 90–97.